Table 3.
Characteristics of cGVHD after preemptive IFN-α treatment.
| Characteristics of cGVHD | IFN-α group (n = 68) |
|---|---|
| Time from cGVHD to immunotherapy, days (range) | 43 (1–404) |
| Severity of cGVHD, n (%) | |
| None | 41 (60.3) |
| Mild | 10 (14.7) |
| Moderate | 12 (17.6) |
| Severe | 5 (7.4) |
| Type of cGVHD, n (%) | |
| None | 41 (60.3) |
| Classical cGVHD | 24 (35.3) |
| Overlap syndrome | 3 (4.4) |
| Site of cGVHD, n (%) | |
| Skin | 21 (30.9) |
| Mouth | 8 (11.8) |
| Eye | 4 (5.9) |
| Liver | 7 (10.3) |
| Gut | 5 (7.4) |
| Lung | 5 (7.4) |
| Number of sites, n (%) | |
| 0 | 41 (60.3) |
| 1 | 14 (20.6) |
| 2 | 7 (10.3) |
| ≥ 3 | 6 (8.8) |
Data was present as n (%) or median (range).
cGVHD chronic graft-versus-host disease, IFN-α interferon-α.